RS67706B1 - Čvrsti oblici 2-(5-(4-(2-morfolinoetoksi)fenil)piridin-2-il)-n-benzilacetamida - Google Patents

Čvrsti oblici 2-(5-(4-(2-morfolinoetoksi)fenil)piridin-2-il)-n-benzilacetamida

Info

Publication number
RS67706B1
RS67706B1 RS20251351A RSP20251351A RS67706B1 RS 67706 B1 RS67706 B1 RS 67706B1 RS 20251351 A RS20251351 A RS 20251351A RS P20251351 A RSP20251351 A RS P20251351A RS 67706 B1 RS67706 B1 RS 67706B1
Authority
RS
Serbia
Prior art keywords
exemplary embodiment
compound
solvent
weeks
approximately
Prior art date
Application number
RS20251351A
Other languages
English (en)
Serbian (sr)
Inventor
Michael P Smolinski
Original Assignee
Atnx Spv Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65517772&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS67706(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Atnx Spv Llc filed Critical Atnx Spv Llc
Publication of RS67706B1 publication Critical patent/RS67706B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56—Amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Plural Heterocyclic Compounds (AREA)
RS20251351A 2017-09-07 2018-09-07 Čvrsti oblici 2-(5-(4-(2-morfolinoetoksi)fenil)piridin-2-il)-n-benzilacetamida RS67706B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762555390P 2017-09-07 2017-09-07
PCT/US2018/049829 WO2019051147A1 (en) 2017-09-07 2018-09-07 SOLID FORMS OF 2- (5- (4- (2-MORPHOLINOETHOXY) PHENYL) PYRIDIN-2-YL) -N-BENZYLACETAMIDE
EP18854688.1A EP3679016B1 (en) 2017-09-07 2018-09-07 Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide

Publications (1)

Publication Number Publication Date
RS67706B1 true RS67706B1 (sr) 2026-02-27

Family

ID=65517772

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20251351A RS67706B1 (sr) 2017-09-07 2018-09-07 Čvrsti oblici 2-(5-(4-(2-morfolinoetoksi)fenil)piridin-2-il)-n-benzilacetamida

Country Status (23)

Country Link
US (4) US10669236B2 (https=)
EP (2) EP4674486A3 (https=)
JP (3) JP7843116B2 (https=)
KR (2) KR102691700B1 (https=)
CN (2) CN111278808B (https=)
AU (2) AU2018330163B2 (https=)
BR (1) BR112020004419A2 (https=)
CA (1) CA3074831A1 (https=)
DK (1) DK3679016T3 (https=)
ES (1) ES3056703T3 (https=)
FI (1) FI3679016T3 (https=)
HR (1) HRP20260002T1 (https=)
IL (2) IL326637A (https=)
LT (1) LT3679016T (https=)
MX (2) MX2020002622A (https=)
PL (1) PL3679016T3 (https=)
PT (1) PT3679016T (https=)
RS (1) RS67706B1 (https=)
SG (1) SG11202001868RA (https=)
SI (1) SI3679016T1 (https=)
SM (1) SMT202500467T1 (https=)
TW (1) TWI815820B (https=)
WO (1) WO2019051147A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7968574B2 (en) * 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
EP4186890A1 (en) 2021-11-29 2023-05-31 Moehs Ibérica, S.L. Preparation of n-benzyl-2-(5-bromo-pyridin-2-yl)-acetamide for the synthesis of tirbanibulin
CN115010655A (zh) * 2022-07-21 2022-09-06 重庆迈德凯医药有限公司 一种替尼布林的纯化方法
WO2026022219A1 (en) 2024-07-24 2026-01-29 Almirall, S.A. Injectable formulations comprising tirbanibulin

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
ES2258142T3 (es) * 2001-05-22 2006-08-16 Pfizer Products Inc. Nueva forma cristalina.
US6821502B2 (en) * 2002-06-12 2004-11-23 Chevron U.S.A. Inc. Method of making aluminum-containing zeolite with IFR structure
US7351833B2 (en) * 2004-07-23 2008-04-01 Abbott Laboratories (1S,5S)-3-(5,6-dichloropyridin-3-yl)-3,6-diazabicyclo[3.2.0]heptane benzenesulfonate
US7968574B2 (en) 2004-12-28 2011-06-28 Kinex Pharmaceuticals, Llc Biaryl compositions and methods for modulating a kinase cascade
ES2382068T3 (es) 2004-12-28 2012-06-05 Kinex Pharmaceuticals, Llc Composiciones y métodos para tratar trastornos de proliferación celular
MY152185A (en) * 2005-06-10 2014-08-29 Novartis Ag Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
CN101687905A (zh) * 2005-09-13 2010-03-31 西科尔公司 纯罗库溴铵
ES2500165T3 (es) 2006-06-29 2014-09-30 Kinex Pharmaceuticals, Llc Composiciones de biarilo y métodos para modular una cascada de quinasas
MX2009003405A (es) * 2006-09-28 2009-04-09 Merck & Co Inc Composiciones farmaceuticas de inhibidores de la histona desacetilasa y compuestos quelantes de metal, y complejos de quelato de metal-inhibidor de histona desacetilasa.
US7837978B2 (en) * 2006-10-13 2010-11-23 Chevron U.S.A. Inc. Process for preparing aluminum-containing molecular sieve SSZ-26
PE20081506A1 (es) * 2006-12-12 2008-12-09 Infinity Discovery Inc Formulaciones de ansamicina
US7935697B2 (en) * 2006-12-28 2011-05-03 Kinex Pharmaceuticals, Llc Compositions for modulating a kinase cascade and methods of use thereof
US7939529B2 (en) 2007-05-17 2011-05-10 Kinex Pharmaceuticals, Llc Process for the preparation of compositions for modulating a kinase cascade and methods of use thereof
TWI457336B (zh) * 2006-12-28 2014-10-21 Kinex Pharmaceuticals Llc 調節激酶級聯之組成物及方法
AU2008253803A1 (en) * 2007-05-22 2008-11-27 Ultimorphix Technolgies B.V. Tenofovir disoproxil hemi-fumaric acid Co-crystal
WO2015069217A1 (en) * 2013-11-05 2015-05-14 Baylor College Of Medicine Src kinase inhibition as treatment for lympangioleiomyomatosis and tuberous sclerosis
CN106810490A (zh) * 2017-02-06 2017-06-09 重庆泰润制药有限公司 一种二芳基化合物的晶型及其制备方法和应用
FI3592355T3 (fi) 2017-03-10 2026-02-13 Atnx Spv Llc KX2-391/KX-01 käytettäväksi aktiinisen keratoosin hoidossa

Also Published As

Publication number Publication date
CN111278808B (zh) 2024-04-26
PL3679016T3 (pl) 2026-03-02
AU2023201010A1 (en) 2023-03-23
US20190071402A1 (en) 2019-03-07
DK3679016T3 (da) 2025-12-15
IL272992A (en) 2020-04-30
JP2025131661A (ja) 2025-09-09
PT3679016T (pt) 2025-12-05
HRP20260002T1 (hr) 2026-02-27
ES3056703T3 (en) 2026-02-24
SMT202500467T1 (it) 2026-03-09
US20220098152A1 (en) 2022-03-31
CN111278808A (zh) 2020-06-12
US20200255380A1 (en) 2020-08-13
CN118439992A (zh) 2024-08-06
AU2018330163A1 (en) 2020-03-26
US10669236B2 (en) 2020-06-02
KR102691700B1 (ko) 2024-08-02
CA3074831A1 (en) 2019-03-14
AU2018330163B2 (en) 2023-02-02
SG11202001868RA (en) 2020-03-30
SI3679016T1 (sl) 2026-04-30
MX2023001805A (es) 2023-03-13
EP3679016B1 (en) 2025-11-05
RU2020112539A3 (https=) 2022-04-19
FI3679016T3 (fi) 2025-12-12
MX2020002622A (es) 2020-10-01
AU2023201010B2 (en) 2024-10-03
EP4674486A3 (en) 2026-03-25
KR20240119192A (ko) 2024-08-06
KR20200081359A (ko) 2020-07-07
US12215083B2 (en) 2025-02-04
LT3679016T (lt) 2026-02-10
RU2020112539A (ru) 2021-10-08
EP4674486A2 (en) 2026-01-07
JP2020533412A (ja) 2020-11-19
BR112020004419A2 (pt) 2020-09-08
WO2019051147A1 (en) 2019-03-14
US20250115555A1 (en) 2025-04-10
IL326637A (en) 2026-04-01
EP3679016A1 (en) 2020-07-15
EP3679016A4 (en) 2021-09-29
JP2023157909A (ja) 2023-10-26
JP7843116B2 (ja) 2026-04-09
US11230527B2 (en) 2022-01-25
TWI815820B (zh) 2023-09-21
TW201920160A (zh) 2019-06-01

Similar Documents

Publication Publication Date Title
US12215083B2 (en) Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide
AU2018241172A1 (en) Preparation, uses and solid forms of obeticholic acid
TW201443001A (zh) 雙環止痛化合物
CN110461836B (zh) 一种选择性抑制激酶化合物及其用途
JP2026041824A (ja) テガビビントの結晶形態、調製方法、及びその使用
TWI771280B (zh) 經取代之5,6-二氫-6-苯基苯并[f]異喹啉-2-胺化合物之固體形式
JP6961348B2 (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物の塩および多型
RU2802964C2 (ru) Твердые формы 2-(5-(4-(2-морфолиноэтокси)фенил)пиридин-2-ил)-n-бензилацетамида
JP7184302B2 (ja) ヒトトレフォイル因子３の阻害に有用な化合物
HK40115548A (zh) 2-(5-(4-(2-吗啉代乙氧基)苯基)吡啶-2-基)-n-苄基乙酰胺的固体形式
TWI898321B (zh) 用於治療或預防高尿酸血症或痛風的化合物的固體晶型
CN105566302A (zh) 二氢吲哚酮化合物及其盐的结晶
CA3101143A1 (en) Salt form
CN102666528A (zh) 晶体cdc7 抑制剂盐
CN121941687A (zh) 一种丙烯酰胺类化合物的晶型vi及其制备方法和用途